Phase III GEMSTONE-302 study demonstrates clinical benefit of sugemalimab plus chemotherapy in treating NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Updated results from CStone Pharmaceuticals’ phase III GEMSTONE-302 study indicate the effectiveness of the antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with stage IV non-small cell lung cancer. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login